Rx-360 Selects BSI Supply Chain Solutions to Lead Its International Joint Audit Program
Rx-360 announces a strategic partnership with BSI Supply Chain Solutions on Rx-360’s Joint Audit Program designed to enhance patient safety and increase supply chain security through on-the-ground supplier audits.
One of the world’s leading business solutions providers, BSI shares in Rx-360’s commitment to patient safety with its long history ensuring quality and consistency.
BSI will work with Rx-360 to further streamline the audit process and ensure supplier compliance with quality and security standards through verification audits. Overall security will be strengthened through improved supply chain transparency and visibility.
Rx-360, a not-for-profit international consortium representing the world’s leading pharmaceutical and biotech organizations, is committed to protecting patient safety. Recognizing that the globalization of suppliers has added significant complexity to ensuring supplier quality and security of the supply chain, Rx-360 has developed the Joint Audit program to verify and validate supplier compliance, enhance supply chain integrity and improve quality.
This innovative approach will allow multiple companies working with the same business partner to participate in a standardized audit without sacrificing product or process confidentiality. This in turn will significantly reduce audit costs, standardize the audit scope, expand the number of audits conducted, and ultimately reduce supplier audit fatigue while maintaining a high quality standard. The Joint Audit program will ensure audit consistency and transparency from audit scheduling through the required Corrective and Preventive Actions.
BSI was selected for this engagement following a thorough RFP process that considered more than a dozen other highly-qualified auditing firms. Rx-360 has chosen a partner in BSI that has proven its commitment to patient safety through its extensive work in the medical device industry.
With more than 70,000 clients worldwide and more than 150,000 audit days in 150 countries per year, BSI has the resources and infrastructure required to assist Rx-360 with their audit needs and is perfectly positioned to serve as a partner with Rx-360 members’ supplier base.
BSI will utilize its Supplier Verification (VerifEYE) services which will provide local personnel familiar with the local language, customs and traditions to conduct the audits. To ensure consistency of audits, these auditors will be trained by BSI Supply Chain Solutions to standards specific to Rx-360 members’ auditing requirements, including cGMP regulations as well as supply chain security.
Dan Purtell, Senior Vice President, Supply Chain Solutions stated: “By incorporating BSI’s extensive history of corporate auditing, our reputation in the medical device community for patient-safety, and our cutting-edge risk-based approach to supply chain security, we are able to offer Rx-360 a unique solution to meet their needs for efficient and comprehensive supplier auditing. This award will help Rx-360 members significantly reduce ineffective and overlapping audits while maintaining the overarching goal of increasing patient safety.”
Ben Mills, Co-Chair of Rx-360’s Audit Operations Group stated: “Rx-360’s primary mission is to ensure patient safety by maintaining high standards of quality during the manufacturing process. The Joint Audit program will allow consortium members to pool resources and have third-party audits conducted simultaneously while protecting commercially-sensitive and proprietary information. With BSI Supply Chain Solutions, Rx-360 has a partner known for experience, confidentiality, and quality. BSI’s risk-based approach to auditing will enhance effectiveness and supply chain security. The Joint Audit Program offers consortium members, suppliers and manufacturers alike, the opportunity to reduce the audit burden while amplifying product confidence and safety.”
BSI’s integration into Rx-360’s Joint Audit program will begin later this summer.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance